Ecromeximab Biosimilar - Research Grade

Human

ganglioside GD3 [Homo sapiens]

>1mg/ml

IgG1 - kappa

CHO Cells

Mitumomab Biosimilar - Research Grade (ICH5690)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the originator antibody ecromeximab, offered strictly for research use only. It reproduces the antigen-binding specificity of the parent molecule, which recognizes the disialoganglioside GD3, a glycosphingolipid antigen strongly associated with melanoma and other neuroectodermal tumors. The molecule is a human IgG1/kappa format suitable for studies that require an Fc-competent, GD3-directed binder. It is not the clinical drug and is not intended for human or veterinary use. Supplied unconjugated, it is well suited to controlled laboratory work: positive and isotype-matched controls, binding and epitope characterization, neutralization and blocking assays, ADCC/CDC readouts, and as a benchmarking reagent during antibody-drug conjugate or CAR development against GD3. Material is manufactured to a research-grade, low-endotoxin specification (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities for in-vitro and preclinical model work. As a biosimilar analog it enables reproducible, cost-effective comparisons to originator reference material without clinical-grade constraints. GD3 is a b-series disialoganglioside, a sialic-acid-bearing glycosphingolipid built on a lactosylceramide core (Neu5Ac-Neu5Ac-Gal-Glc-ceramide). It is synthesized from GM3 by GD3 synthase (ST8SIA1/ST8Sia I), which adds a second sialic acid. GD3 is abundant in the developing nervous system and neural crest but is expressed at low levels in most normal adult tissues. It becomes markedly over-expressed on melanoma and other neuroectoderm-derived tumors, making it a recognized tumor-associated antigen. At the cell surface GD3 resides in lipid-raft microdomains where it modulates receptor signaling, cell adhesion, and migration; intracellularly, GD3 accumulation has been linked to mitochondrial apoptotic signaling. Its restricted normal distribution combined with tumor over-expression underpins interest in GD3 as a target for antibody-based, ADC, and cellular immunotherapy strategies.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Ecromeximab biosimilar available in bulk or gram quantities?

A: Yes — the Ecromeximab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Ecromeximab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ecromeximab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ecromeximab that binds ganglioside GD3 [Homo sapiens].